February 3, 2021 10:54 AM EST
News Briefing

Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

Nicole DeFeudis

Editor

On a mis­sion to sub­due the ris­ing glob­al threat of an­tibi­ot­ic re­sis­tance, the CARB-X ini­tia­tive has inked yet an­oth­er grant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

Ex­clu­sive: Blood stem cell ther­a­py mak­er Garu­da gets new CEO, adds $47M

FDA re­moves hold on three CARs­gen CAR-T tri­als; Ono pass­es on itolizum­ab

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

A service from the Financial Times